The news: More than 60 healthcare and technology players, including Amazon, Apple, Google, UnitedHealth Group, and OpenAI, signed a voluntary pledge put forth by the Trump administration to make it easier for consumers to access their medical data. Our take: It’s not the first time that industry players have pledged to improve health data sharing—but we haven’t seen enough progress due to a lack of accountability or enforcement. Many consumers also likely have concerns about how tech companies will use and protect their personal information.
The trend: Older consumers pick up their prescription medicines in person more often, while Gen Z looks to buy Rx drugs online, per M3 MI’s Consumer Health Study of over 20,000 US adults. The takeaway: Drugmakers can lean into tailored marketing efforts that match age demographics and retail preferences. Amazon Pharmacy doesn’t take ads, but pharma companies can show young people getting Amazon Rx deliveries. On the flip side, feature older actors or promote vaccine messages via retail media in grocery stores.
The news: The trade deal between the US and EU will include a 15% tariff on pharmaceuticals imported from Europe, the White House said. The final word: Pharma companies and industry trade groups had been holding out hope that their medicines imported to the US would be exempt from tariffs. Not getting that reprieve is a setback—but the 15% rate on its own could be seen as a decent outcome, particularly considering that 200% tariffs were threatened and the Section 232 investigation could lead to a higher levy in other countries.
The news: Novo Nordisk’s stock plunged over 20% on Tuesday after it cut full-year guidance, citing lower-than-expected sales growth for Wegovy, its blockbuster weight loss drug. Our take: Despite the recent slump, we think Novo is well positioned to rebound. It remains one of two dominant players in the weight loss drug space and is still posting profit growth, albeit below Wall Street expectations. With the US adult obesity rate expected to hit 50% by 2030, the market opportunity is huge. Meanwhile, regulators are likely going to make it more difficult for compounded drugs to be sold as long as brand-name forms stay off the FDA’s drug shortage list.
The news: HHS Secretary Robert F. Kennedy Jr. is expected to remove all 16 members of a task force that advises the government on preventive health services due to the committee being perceived as too “woke,” according to a report in The Wall Street Journal. Our take: A complete overhaul of another important panel of medical experts could reduce patient access to critical preventive care while confusing doctors about which guidelines to rely on—especially if Kennedy chooses replacements based on politics and like-minded beliefs rather than health expertise.
The trend: Hispanic and Black people are underrepresented in the clinician workforce compared to the broader US population, according to a KFF analysis of 2023 industry data. Our take: Diversity impacts where patients feel most comfortable seeking healthcare. Providers and marketers should invest in multilingual staff and partner with local community groups that have established relationships with diverse consumers.
The news: More than 90% of multicultural consumers use digital devices in their healthcare journeys, per a new Cadent Pharma Advertising Trends study. The takeaway: TV is still an important broad awareness media channel for pharma and healthcare companies. However, among growing diverse populations, digital and mobile advertising is more popular and spurs a desire for more information and purchasing. Marketers need to meet diverse audiences with educational and culturally relevant content.
The news: The popular physical fitness goal of 10,000 steps per day may be getting an overhaul with new research that found 7,000 steps per day offers significant health benefits and lowers risk of serious disease. The takeaway: Health and fitness marketers can use the new 7,000-step results as a motivator. Key in on the lowered goal in marketing messages—7,000 is the new 10,000—and use non-judgemental and friendly language. Tap influencers to spread the word that the more achievable goal means much better health.
The trend: GenAI tools like ChatGPT are providing fewer disclaimers that chatbots are not a substitute for professional medical advice, according to a recent study cited in MIT Technology Review. Our take: Tech players must prioritize user safety—not winning the AI race. Health warnings should be standard, and marketers will need to scale back claims that AI accuracy surpasses physicians’.
As more consumers start GLP-1 treatments, some CPG brands must work harder to stay in shopping carts. As many GLP-1 users eat less and change their diets, it opens new challenges and opportunities for retailers and marketers.
The news: Prescription drugmakers can now apply for new Trump administration priority review vouchers that will cut drug approval times down from 10-12 months to just 1-2 months. Our take: Good faith commitments for US drug onshoring investments could translate to valuable advantages if those drugmakers can leverage those into a CNPV. But with so many pharma companies already in that pool, we expect this year’s winners to be drugmakers who can show real evidence of two, three or even all five priorities on the Trump administration list.
The news: Roche is considering a direct-to-patient (D2C) sales channel for its prescription drugs, CEO Thomas Schinecker said in its Q2 earnings call. Our take: The complex US healthcare PBM and insurance system can’t easily flip to a pure-play D2C prescription sales market. However, we think it will become a reliable channel, especially for self-pay patients. Pharma marketers can court them with special pricing deals, a la Lilly and Novo, but ensure they stay on the right side of regulators.
The trend: Consumers generally find that AI-generated responses to their online health queries are only somewhat reliable, according to a new survey from the Annenberg Public Policy Center (APPC) of the University of Pennsylvania. Our take: As Google’s AI gets smarter, healthcare and pharma websites will lose search traffic. Google is in a race with OpenAI and other tech players to make its AI more intelligent and improve users’ search experiences. Other consumers will conduct more health queries on platforms like ChatGPT. Brands and publishers must optimize content for AI rather than for search, but they should also be developing strategies to connect more with consumers on non-search channels such as social media and CTV.
The news: Due to confusing guidance from the federal government, medical associations and several states are creating their own vaccine recommendations for the public, per a Reuters report. Our take: Next, pharma brands and marketers—particularly vaccine makers—must preserve the integrity of their products by creating ad campaigns that directly address the safety concerns called out by RFK Jr. and his team.
The news: AstraZeneca plans to invest $50 billion in US drug manufacturing and R&D by 2030. The big takeaway: Pouring billions into US builds isn’t an option for most generic drugmakers that operate on thin margins. This could result in shortages since companies that make generics may have to choose between exiting the market once tariffs take effect and raising prices when possible. Other players in this space might find it most beneficial to wait it out and see if Trump changes course yet again on tariff policy.
The news: Rare disease drugmaker Sarepta Therapeutics is pausing sales of a muscular dystrophy drug, Elevidys, after initially refusing an FDA request to halt sales due to safety concerns. The takeaway: Elevydis’ path to FDA approval was unconventional, but deemed appropriate at the time for a devastating disease. The new deaths and now paused sales serve as caution for both the FDA and drugmakers to balance the emotional sway of unmet medical needs with complete and continued clinical research.
The news: Insurance premiums are set to rise by 15% next year for the people who buy through the Affordable Care Act, per a new KFF analysis. Our take: While the Trump administration is eliminating the ACA tax credits, states where the president won the election account for 88% of ACA enrollment growth since 2020, per KFF research in April. When premium increases roll out across the ACA marketplace, and spillover into higher costs for hospitals and healthcare services, we expect plenty of political finger-pointing over fault, but little agreement on ways to improve US healthcare and keep consumers out of medical debt.
The trend: Consumer perception of healthcare providers worsens when they find out the doctor uses AI, according to research recently published in JAMA Network. Our take: Healthcare is inherently emotional, and many consumers might be under the impression that their doctor is using AI as a shortcut. In reality, the opposite might be true. Physicians use AI to make them more efficient and free them up to spend extra time with patients. But language and details matter, and providers and marketers must ensure this is reflected in their messaging.
The trend: People who actively use patient portals are less likely to skip an upcoming doctor’s appointment than those without portal accounts, according to recent research from Epic that analyzed 1.6 billion visits in 2024. Our take: Engaging with a patient portal is important, but it isn’t a major needle mover for appointment no-shows. Strategies such as helping coordinate transportation, sending text and email alerts, and communicating no-show fees could play a bigger role in eliminating costly no-shows.
The news: Abbott and Johnson & Johnson reported lower-than-expected costs from tariffs during Q2 earnings this week. Our take: It seemed like medical device companies would be the hardest hit by tariffs initially. So the positive spin from Abbott and J&J is encouraging. But tariffs are still costly. While device and diagnostic companies talk broadly about plans to mitigate tariff effects, raising prices for healthcare systems and consumers isn’t off the table.